Concise verdict

The 2020 FASEB study (DOI: 10.1096/fj.201902938RR) designed ASC- and NLRP3-derived peptides and identified a selective NLRP3 inhibitor (ASCPYD/H2-H3) that binds NLRP3PYD (micromolar SPR), blocks IL-1β maturation, caspase‑1 activation and ASC specking in vitro, crosses mouse BBB when tagged (Angiopep‑2 or Antennapedia), and reduces neutrophil infiltration in silica peritonitis in vivo — promising as a mechanistic tool and lead, but limited by small animal group sizes (3–5), partial NF-κB/other-inflammasome off-target effects for some peptides, peptide solubility/delivery and lack of human validation Sušjan et al., FASEB J. 2020

Visual paper review — Sušjan et al., FASEB J. (2020)

Key visual summary

Core claims (visual then text)

Text-first summary (evidence-linked)

• Designed nine peptides from ASC and NLRP3 domains; five inhibited IL‑1β release and caspase‑1 activation across particulate and soluble NLRP3 triggers (nanoSiO2, ATP, nigericin) in murine iBMDMs and microglia Peptide screen and in vitro assays
• ASCPYD/H2-H3 is the only peptide reported to be NLRP3‑selective (no inhibition of AIM2/NLRC4 or NF‑κB at working concentrations) and binds purified NLRP3PYD in SPR in the micromolar range (plateau not reached due to peptide solubility) ASCPYD/H2-H3 selectivity and SPR
• ASCPYD/H2-H3 reduces ASC speck formation, caspase‑1 p20 in supernatant, and active caspase‑1 signal by FAM‑FLICA; peptide did not change pro‑IL‑1β levels, indicating action on processing rather than priming Functional downstream readouts
• Angiopep‑2 or Antennapedia tags permit BBB penetration and brain retention of TMR‑labeled ASCPYD/H2-H3 in mice (IVIS and histology); Angiopep‑2-ASCPYD/H2-H3 retained in brain at 3 h while untagged peptide cleared quickly BBB crossing experiments
• In vivo efficacy: intraperitoneal ASCPYD/H2-H3 reduced neutrophil infiltration in silica-induced peritonitis (3–5 mice/group; unrandomized, no power calculation) Peritonitis in vivo results

Critical appraisal — strengths

• Rational, structure-based peptide design targeting defined interaction surfaces (PYD H2–H3, CARD H2–H3, NACHT motifs) using published structural models and sequence alignments, enabling mechanism-focused modulation Peptide design rationale
• Multiple orthogonal readouts: ELISA for IL‑1β, FAM‑FLICA flow cytometry for active caspase‑1, Western blot of caspase‑1 p20 and pro‑IL‑1β, ASC speck confocal imaging and SPR binding — increases confidence in mechanistic interpretation Multiplexed assay approach
• Translation-focused experiments (BBB tags, in vivo peritonitis) strengthen claim that peptides can function beyond cell culture." In vivo translation experiments

Critical appraisal — limitations, caveats, and blindspots

1. Small animal groups and lack of randomization/blinding reduce confidence in in vivo efficacy; per-author note: groups were 3–5 mice without power calculation — risk of false positives/Type I error Small animal group sizes
2. SPR binding reported but Kd uncertain due to peptide solubility and lack of plateau — micromolar binding claimed but quantitative affinity remains imprecise; kinetic parameters not reported SPR limitations and solubility
3. Potential off-target effects: several peptides (eg NLRP3WalkerB, NLRP3Sensor1) affected NF‑κB and also inhibited AIM2/NLRC4 — this broad activity reduces their utility as selective probes and raises toxicity/side-effect concerns if developed therapeutically Off-target and NF-kB effects
4. Delivery & stability: peptides require myristoylation or internalization tags and still exhibited limited solubility; in vivo PK/PD, proteolysis, immunogenicity, and dose–response were not characterized fully — crucial for therapeutic translation.
5. Species and cell models: all primary functional data derive from murine iBMDMs and immortalized microglia; human primary cell validation (human macrophages/microglia) is absent, limiting translational extrapolation.
6. Pyroptosis readout: authors report that LDH (pyroptosis) was not reduced despite lowered caspase‑1 activity — suggests partial inhibition or threshold effects where residual caspase activity is sufficient for pyroptotic outcomes; mechanism for this disconnect not explored in detail Discordant pyroptosis results

Reproducibility and technical clarity

Methods are described in substantial detail (peptide prep, concentrations, LPS priming, stimulants, ELISA, Western, SPR ligand/analyte handling, microscopy settings). Key reproducibility concerns: no raw numerical datasets deposited, SPR reported without kinetic fits/Kd, and small in vivo group sizes. Overall reproducibility score is moderate but feasible for labs with peptide synthesis and inflammasome expertise Methods transparency

Overall assessment (numeric)

Practical recommendations to advance this line

1. Determine Kd and kinetics for ASCPYD/H2-H3–NLRP3PYD with higher-solubility variants or using immobilized-peptide format; complement with isothermal titration calorimetry (ITC) and/or microscale thermophoresis (MST) for orthogonal affinity data.
2. Solve a co-structure (cryo-EM or NMR) of NLRP3PYD bound to peptide or a peptide-stabilized PYD complex to map interaction surface and optimize design (stapling, D-amino acids) for potency/stability.
3. Test in human primary macrophages/microglia and in relevant human iPSC-derived microglia to validate translational relevance.
4. Expand in vivo studies with proper power calculations, randomization/blinding, PK/PD, immunogenicity, and dose-response; assess behavioral/cognitive endpoints for CNS delivery context if neurodegeneration models are used.

What would disprove the central claims?

• Failure of optimized ASCPYD/H2-H3 (improved solubility/stability) to bind NLRP3PYD in orthogonal biophysical assays (ITC/MST) would refute the specific binding mechanism.
• Absence of efficacy in well-powered, randomized animal models or in human primary cells would falsify therapeutic potential.
• If structural mapping shows peptide binds ASC rather than NLRP3PYD or simply aggregates proteins non-specifically, the selectivity claim would be undermined.

Short, actionable bioinformatics/experimental code suggestion

Buttons — run further BGPT actions

Primary citation

Sušjan et al., FASEB J. 2020

Confidence, next steps, and closing note

Confidence in the main experimental claims (peptide activity in murine cells and binding evidence) is moderate (7/10) given orthogonal assays; confidence in translational therapeutic potential is lower (4–5/10) until quantitative affinity, PK/PD, immunogenicity and human primary cell data are provided. The paper delivers a valuable mechanistic tool (ASCPYD/H2-H3) and a promising lead for CNS-capable peptide modulators — but further quantitative biophysics and well-powered in vivo validation are necessary.